SG Americas Securities
FLNA

SG Americas Securities’s Filana Therapeutics FLNA Stock Holding History

SG Americas Securities’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$605K – 3511
2022
Q2 		$605K Buy
+50,000
New +$1.26M 0.01% 1792
2021
Q4 		– Sell
-130,000
Closed -$3.42M – 3759
2021
Q3 		$3.42M Buy
+130,000
New +$10.8M 0.02% 815

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

SG Americas Securities's FLNA Position: Q2 2025 in Review

SG Americas Securities sold out of Filana Therapeutics (FLNA) in Q2 2025, closing a stake of 29,949 shares — an estimated $45K sold.

SG Americas Securities first reported a position in FLNA in Q2 2014 and held it in 17 quarters. The position peaked at $8.87M in Q3 2021. 97 funds tracked by Wall St. Rank hold FLNA as of Q2 2025.

  • SG Americas Securities reported no remaining Filana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 29,949 Filana Therapeutics shares in Q2 2025, an estimated $45K.
  • SG Americas Securities first reported a position in Filana Therapeutics in Q2 2014 and held it in 17 quarters.
  • SG Americas Securities's Filana Therapeutics position peaked at $8.87M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.